Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies
Could Be Worth $900m
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.
You may also be interested in...
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.